709 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
AMGN Amgen Inc. $200.81 $129.98B N/A
Article Searches
Amgen to Acquire Dezima Pharma, Strikes Deal with Xencor http://www.zacks.com/stock/news/190477/amgen-to-acquire-dezima-pharma-strikes-deal-with-xencor?cid=CS-ZC-FT-190477 Sep 17, 2015 - Amgen (AMGN), to buy cardiovascular focused company, Dezima Pharma, strikes a deal with Xencor targeting areas of cancer immunotherapy and inflammation.
Amgen Seeks FDA Approval for Repatha's New Dosing Option http://www.zacks.com/stock/news/189982/amgen-seeks-fda-approval-for-repathas-new-dosing-option?cid=CS-ZC-FT-189982 Sep 14, 2015 - Amgen (AMGN) is looking to gain FDA approval for a 420 mg monthly dose of Repatha to be given as a single injection.
Will Kite (KITE) Get Orphan Status Again in EU for KTE-C19? http://www.zacks.com/stock/news/189966/will-kite-kite-get-orphan-status-again-in-eu-for-kte-c19?cid=CS-ZC-FT-189966 Sep 14, 2015 - The COMP has adopted a positive opinion regarding the granting of orphan drug status to Kite's (KITE) KTE-C19 for the treatment of PMBCL and MCL.
Stock Market News for September 11, 2015 http://www.zacks.com/stock/news/189724/stock-market-news-for-september-11-2015?cid=CS-ZC-FT-189724 Sep 11, 2015 - Benchmarks ended modestly higher on Thursday amid rise in oil prices and uncertainty about the timing of a rate hike
The Zacks Analyst Blog Highlights: Amgen, Tetraphase, Geron, Alexion and ACADIA http://www.zacks.com/stock/news/189574/the-zacks-analyst-blog-highlights-amgen-tetraphase-geron-alexion-and-acadia?cid=CS-ZC-FT-189574 Sep 10, 2015 - The Zacks Analyst Blog Highlights: Amgen, Tetraphase, Geron, Alexion and ACADIA
Biotech Stock Roundup: Biosimilar Competition for Amgen, Tetraphase Hit By Disappointing Data http://www.zacks.com/stock/news/189412/biotech-stock-roundup-biosimilar-competition-for-amgen-tetraphase-hit-by-disappointing-data?cid=CS-ZC-FT-189412 Sep 09, 2015 - What will be the impact of biosimilar competition on Amgen's (AMGN) Neupogen now that Zarxio has been launched in the U.S.?
Stock Market News for September 09, 2015 http://www.zacks.com/stock/news/189402/stock-market-news-for-september-09-2015?cid=CS-ZC-FT-189402 Sep 09, 2015 - Benchmarks ended higher on Tuesday after weak Chinese trade data raised hopes that further stimulus measures will be announced to boost its fragile economy
Novartis (NVS) Launches Zarxio: First Biosimilar in the U.S. http://www.zacks.com/stock/news/188907/novartis-nvs-launches-zarxio-first-biosimilar-in-the-us?cid=CS-ZC-FT-188907 Sep 03, 2015 - Novartis (NVS) launched Zarxio (biosimilar version of Amgen's Neupogen) in the U.S., which became the first FDA-approved biosimilar to be launched in the country.
The Zacks Analyst Blog Highlights: Amgen, ARIAD, Celgene, Amicus and Alnylam http://www.zacks.com/stock/news/188832/the-zacks-analyst-blog-highlights-amgen-ariad-celgene-amicus-and-alnylam?cid=CS-ZC-FT-188832 Sep 03, 2015 - The Zacks Analyst Blog Highlights: Amgen, ARIAD, Celgene, Amicus and Alnylam
Amgen, Novartis Team Up; Bone Drug Positive in Phase III http://www.zacks.com/stock/news/188757/amgen-novartis-team-up-bone-drug-positive-in-phase-iii?cid=CS-ZC-FT-188757 Sep 02, 2015 - Amgen (AMGN) inks deal with Novartis for Alzheimer's disease and migraine; reports positive phase III data on romosozumab.

Pages: 1...65666768697071

<<<Page 70